Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin of $3.06M in Q2 FY2026

Q2 FY2026 selling, general & admin was $3.06M.

Context

  • Selling, general & admin amounted to 1003.9% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.06M+3.2% QoQ
Last fiscal yearDec 2025
$13.55M+83.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+83.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
13.55M USD
Year-over-year change
+83.7%
1-year CAGR
+83.7%

Selling, General & Admin vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +83.7% is the highest of 10, against a peer median of +17.2%.
  • Selling, general & admin amounts to 1003.9% of revenue for ATTO, versus a peer median of 248.1%.
ATTO Competitors
Selling, General & Admin for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$77.08M USD+17.2%+94.2%1041.9%
ANABAnaptysBio, Inc.LTM Mar 2026$62.81M USD+42.2%+11.5%27.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$46.46M USD+34.5%+22.2%—
ZURAZura Bio LimitedLTM Mar 2026$35.14M USD+1.0%+112.2%—
ORKAOruka Therapeutics, Inc.LTM Sep 2026$29.26M USD+41.9%+59.4%—
EVMNEvommune, Inc.LTM Mar 2026$22.64M USD——226.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M USD+5.5%-4.4%269.8%
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M USD+5.8%-0.8%31781.3%
QTTBQ32 Bio Inc.LTM Mar 2026$17.08M USD-4.8%+20.7%31.8%
ATTOAttovia Therapeutics, Inc.FY2025$13.55M USD+83.7%—1003.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€9.82M EUR+63.8%——
Peer median (excluding ATTO) —+17.2%+21.4%248.1%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.